menu
    • menu
    [{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BNT325","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"DB-1312","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"3","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Duality Biologics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"BG-C9074","moa":"||B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Agreement","leadProduct":"DB-1324","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ GSK"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Duality Biologics

    Menu

    Duality Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Avenzo Therapeutics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avenzo, DualityBio Sign License for EGFR/HER3 Antibody-Drug Conjugate

                            Details : Under the licensing agreement, Venzo will develop, manufacture and commercialize AVZO-1418 (DB-1418), a potential best-in-class bispecific ADC for treating neoplasms.

                            Product Name : AVZO-1418

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $50.0 million

                            January 07, 2025

                            Lead Product(s) : DB-1418

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Avenzo Therapeutics

                            Deal Size : $1,200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BG-C9074,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nona Biosciences Updates on DualityBio's ADC Collaboration with BeiGene

                            Details : BeiGene has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an ADC, BG-C9074 (DB-1312) from DualityBio.

                            Product Name : DB-1312

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 03, 2025

                            Lead Product(s) : BG-C9074,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

                            Details : Under the agreement, BeiGene will acquire an exclusive option for a global clinical and commercial license to DB-1312, an investigational antibody-drug conjugate therapy for solid tumors.

                            Product Name : DB-1312

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 30, 2024

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1324

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GSK Turns Back to China in Another Potential $1B+ ADC Deal

                            Details : GSK gains an exclusive option to obtain a license to develop and commercialize a potentially best-in-class ADC candidate, DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau).

                            Product Name : DB-1324

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $30.0 million

                            December 04, 2024

                            Lead Product(s) : DB-1324

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Duality Biologics Expands Adcendo Collaboration via Strategic License Agreement

                            Details : Adcendo exercises its option to utilize Duality's platform to further enhance its first-in-class ADC pipeline and develop highly differentiated novel ADCs for the treatment of hard-to-treat cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Adcendo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT325

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Receive FDA Fast Track for BNT325/DB-1305 Candidate

                            Details : DB-1305 (BNT325) is a next-generation ADC candidate targeting TROP2, evaluated in Phase 1/2 clinical trials for platinum-resistant ovarian epithelial cancer and fallopian tube cancer.

                            Product Name : DB-1305

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 31, 2024

                            Lead Product(s) : BNT325

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : BioNTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Initiate Pivotal Phase 3 Trial of BNT323/DB-1303 in MBC

                            Details : BNT323 (DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2. It is under phase 3 clinical development for the treatment of metastatic breast cancer.

                            Product Name : BNT323

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 22, 2024

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : BioNTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT...

                            Details : BNT323 (DB-1303) is a next-generation Topoisomerase 1 inhibitor, ADC candidate targeting HER2, a cell surface protein. It is under phase 1/2 clinical development for the treatment of HER2-expressing advanced endometrial cancer.

                            Product Name : BNT323

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 21, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Dr...

                            Details : Under the expanded collaboration, BioNTech will develop, manufacture and commercialize DB-1305, a third generation Trop2 ADC molecule built from DualityBio's proprietary DITAC platform, globally, excluding Mainland China, Hong Kong and Macau Special Admi...

                            Product Name : BNT323

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $170.0 million

                            August 07, 2023

                            Lead Product(s) : DB-1303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,670.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed

                            Duality Biologics

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy fo...

                            Details : Under the agreement, BeiGene will acquire an exclusive option for a global clinical and commercial license to DB-1312, an investigational, preclinical antibody-drug conjugate therapy for solid tumors and DualityBio will continue preclinical research and ...

                            Product Name : DB-1312

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : DB-1312

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BeiGene

                            Deal Size : $1,300.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth